Cipla Docks Into China With Manufacturing Plans In Tow
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
You may also be interested in...
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.
Aurobindo has formed a new joint venture with a Chinese partner to supply products for the world’s second-largest pharmaceutical market, as Beijing’s drug procurement reforms gather pace.
A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.